BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 16802848)

  • 1. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic profile of posaconazole.
    Li Y; Theuretzbacher U; Clancy CJ; Nguyen MH; Derendorf H
    Clin Pharmacokinet; 2010 Jun; 49(6):379-96. PubMed ID: 20481649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole: therapeutic review of a new azole antifungal.
    Herbrecht R
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole : a review of its use in the management of invasive fungal infections.
    Scott LJ; Simpson D
    Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Level of evidence for therapeutic drug monitoring of voriconazole].
    Hulin A; Dailly E; Le Guellec C;
    Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
    Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole in clinical practice.
    Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
    J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
    Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and clinical use of voriconazole.
    Thompson GR; Lewis JS
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole.
    Jeu L; Piacenti FJ; Lyakhovetskiy AG; Fung HB
    Clin Ther; 2003 May; 25(5):1321-81. PubMed ID: 12867215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of the triazole antifungal agent voriconazole.
    Mikus G; Scholz IM; Weiss J
    Pharmacogenomics; 2011 Jun; 12(6):861-72. PubMed ID: 21692616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
    Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis).
    Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN
    Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole. UK 109496.
    Drugs R D; 1999 Feb; 1(2):187-8. PubMed ID: 10566023
    [No Abstract]   [Full Text] [Related]  

  • 16. Review of the safety and efficacy of voriconazole.
    Hoffman HL; Rathbun RC
    Expert Opin Investig Drugs; 2002 Mar; 11(3):409-29. PubMed ID: 11866669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole: a new triazole antifungal.
    Sabo JA; Abdel-Rahman SM
    Ann Pharmacother; 2000 Sep; 34(9):1032-43. PubMed ID: 10981251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.